Pyxis Oncology

OverviewSuggest Edit

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with the development of novel antibody-based immunotherapies.

Latest Updates

Employees (est.) (Oct 2019)9(+29%)

Pyxis Oncology Financials and Metrics

Summary Metrics

Founding Date


Pyxis Oncology total Funding

$22 m

Pyxis Oncology latest funding size

$22 m

Time since last funding

3 months ago

Pyxis Oncology investors

Pyxis Oncology's latest funding round in July 2019 was reported to be $22 m. In total, Pyxis Oncology has raised $22 m
Show all financial metrics

Pyxis Oncology Online and Social Media Presence

Embed Graph

Pyxis Oncology Frequently Asked Questions

  • When was Pyxis Oncology founded?

    Pyxis Oncology was founded in 2019.

  • How many employees does Pyxis Oncology have?

    Pyxis Oncology has 9 employees.

  • Who are Pyxis Oncology competitors?

    Competitors of Pyxis Oncology include CytomX Therapeutics, Vivace Therapeutics and Lescarden.